According to the Financial Associated Press on November 13 (Reporter He Fan), during today's earnings conference, Fosun Pharma's Secretary of the Board, Dong Xiaoxian, stated that due to the continued growth of innovative drugs and other factors, the company's performance in Q3 increased year-on-year. Regarding injectable botulinum toxin type A, the chief financial officer, Chen Zhanyu, revealed that the product still needs to complete customs declaration processes according to the relevant requirements for the registration of imported drugs. In addition, the privatization process of Henlius and the accessibility of CAR-T products are also receiving much attention.

Regarding the reasons for the performance increase in Q3, Dong Xiaoxian explained to the Financial Associated Press reporter that there are mainly two points: first, during the same period in 2023, revenues from COVID-related products (including Comirnaty (mRNA COVID vaccine), Jebsua and Azvudine tablets, COVID antigen and nucleic acid test reagents, etc.) significantly decreased year-on-year; second, during the same period, the company disposed of COVID-related products and assets showing signs of impairment and made corresponding provisions for asset impairment. By the first three quarters of 2024, the impact of COVID has been basically eliminated, while the continuous growth of innovative drugs has sustained strong performance growth.

The Q3 report shows that Fosun Pharma achieved total revenue of 10.449 billion yuan in Q3, a year-on-year increase of 12.30%; the net income attributable to shareholders was 0.786 billion yuan, representing a year-on-year rise of 55.43%.

In the medical beauty sector, "the product is supplied by the licensor, and before it is listed and sold in China, it still needs to complete the customs declaration processes according to the relevant registration requirements for imported drugs. The company is actively promoting the timely launch of the product in China." When asked whether the injectable botulinum toxin type A has started to contribute to revenues, Chen Zhanyu responded as such.

On September 9, Fosun Pharma officially announced that its licensed injectable botulinum toxin type A was approved by the National Medical Products Administration for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator supercilii and/or the procerus muscles in adults, making it the sixth approved botulinum toxin in the country, reportedly imported from the USA.

Furthermore, the privatization process of Henlius is also under keen scrutiny. Dong Xiaoxian disclosed that as of now, the Henlius privatization transaction remains under review by the relevant regulatory authorities, pending approval from the Henlius shareholders' meeting and the H-share class shareholders' meeting, and that the voluntary delisting application from Henlius still needs to be approved by the Stock Exchange.

On the evening of June 24, Fosun Pharma announced that its controlled subsidiary, Fosun New Drug, intends to acquire and cancel all existing shares held by other shareholders of Henlius (including H-shares and unlisted shares) for cash and/or share swapping purposes and privatize Henlius.

Furthermore, the chairman of fosun pharma, Wu Yifang, stated that the company will continue to promote the accessibility and affordability of CAR-T products, relying on the country's multi-level medical security system, exploring innovative payment solutions, including actively promoting inclusion in the benefit insurance lists of various provinces and cities, and through deepening cooperation with TPA (Third Party Administrator) and insurance companies, continuously improving patient affordability for new drugs.

Last month, the injection of Akilunai from Fosun Kerry was discussed in three national negotiations, but reporters from Caixin did not find the company at the negotiation site. As of the end of June this year, Akilunai injection has been included in over 110 city benefit insurances and over 80 commercial insurances, with registered treatment centers covering more than 28 provinces and cities across the country, totaling over 170.